These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8160253)

  • 1. Probable metabolic interaction between methadone and fluvoxamine in addict patients.
    Bertschy G; Baumann P; Eap CB; Baettig D
    Ther Drug Monit; 1994 Feb; 16(1):42-5. PubMed ID: 8160253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluoxetine addition to methadone in addicts: pharmacokinetic aspects.
    Bertschy G; Eap CB; Powell K; Baumann P
    Ther Drug Monit; 1996 Oct; 18(5):570-2. PubMed ID: 8885121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A therapeutic use of the methadone fluvoxamine drug interaction.
    DeMaria PA; Serota RD
    J Addict Dis; 1999; 18(4):5-12. PubMed ID: 10631960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone.
    Eap CB; Bertschy G; Powell K; Baumann P
    J Clin Psychopharmacol; 1997 Apr; 17(2):113-7. PubMed ID: 10950475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluvoxamine-methadone interaction.
    Alderman CP; Frith PA
    Aust N Z J Psychiatry; 1999 Feb; 33(1):99-101. PubMed ID: 10197892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Depressive disorders in management of drug dependent patients. Methadone maintenance].
    Laqueille X; Spadone C
    Encephale; 1995 Dec; 21 Spec No 4():11-4. PubMed ID: 8808339
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy.
    Liu P; Foster G; Labadie R; Somoza E; Sharma A
    Antimicrob Agents Chemother; 2007 Jan; 51(1):110-8. PubMed ID: 17074798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers.
    Begré S; von Bardeleben U; Ladewig D; Jaquet-Rochat S; Cosendai-Savary L; Golay KP; Kosel M; Baumann P; Eap CB
    J Clin Psychopharmacol; 2002 Apr; 22(2):211-5. PubMed ID: 11910269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methadone maintenance in the treatment of opioid dependence. A current perspective.
    Zweben JE; Payte JT
    West J Med; 1990 May; 152(5):588-99. PubMed ID: 2190427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Craving despite extremely high methadone dosage.
    de Vos JW; Ufkes JG; van Brussel GH; van den Brink W
    Drug Alcohol Depend; 1996 Mar; 40(3):181-4. PubMed ID: 8861396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of rilpivirine on the pharmacokinetics of methadone in HIV-negative volunteers.
    Crauwels HM; van Heeswijk RP; Vandevoorde A; Buelens A; Stevens M; Hoetelmans RM
    J Clin Pharmacol; 2014 Feb; 54(2):133-40. PubMed ID: 24203510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacology of serotonin uptake inhibitors: focus on fluvoxamine.
    Hrdina PD
    J Psychiatry Neurosci; 1991 Jul; 16(2 Suppl 1):10-8. PubMed ID: 1931931
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical use of methadone.
    Layson-Wolf C; Goode JV; Small RE
    J Pain Palliat Care Pharmacother; 2002; 16(1):29-59. PubMed ID: 14650449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder.
    Hori H; Yoshimura R; Ueda N; Ikenouchi-Sugita A; Umene-Nakano W; Nakamura J
    World J Biol Psychiatry; 2009; 10(4 Pt 2):620-2. PubMed ID: 18609433
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluvoxamine-induced theophylline toxicity.
    DeVane CL; Markowitz JS; Hardesty SJ; Mundy S; Gill HS
    Am J Psychiatry; 1997 Sep; 154(9):1317-8. PubMed ID: 9286199
    [No Abstract]   [Full Text] [Related]  

  • 16. Dolutegravir does not affect methadone pharmacokinetics in opioid-dependent, HIV-seronegative subjects.
    Song I; Mark S; Chen S; Savina P; Wajima T; Peppercorn A; Bala U; Geoffroy P; Piscitelli S
    Drug Alcohol Depend; 2013 Dec; 133(2):781-4. PubMed ID: 24018316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of sertraline on methadone plasma levels in methadone-maintenance patients.
    Hamilton SP; Nunes EV; Janal M; Weber L
    Am J Addict; 2000; 9(1):63-9. PubMed ID: 10914294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New psychopharmacologic studies on methadone: implications for the treatment of opiate dependency].
    Eap CB
    Rev Med Suisse Romande; 2000 Feb; 120(2):111-6. PubMed ID: 10748696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacokinetics interaction between methadone and metamizole: study of 53 cases].
    Domeque Valiente N; Prieto Andrés P; Lozano Ortiz R; Andrés Arribas I
    Med Clin (Barc); 2012 Apr; 138(11):498-9. PubMed ID: 21939993
    [No Abstract]   [Full Text] [Related]  

  • 20. [Carbamazepine-fluvoxamine interaction. Consequences for the carbamazepine plasma level].
    Cottencin O; Regnaut N; Thévenon-Gignac C; Thomas P; Goudemand M; Debruille C; Robert H
    Encephale; 1995; 21(2):141-5. PubMed ID: 7781585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.